LY2784544 (CAS 1229236-86-5)
QUICK LINKS
LY2784544 is a compound utilized in biochemical and molecular biology research, particularly for its role in targeting specific kinase enzymes. Researchers use LY2784544 to study the Janus kinase 2 (JAK2) pathway, which is implicated in various cellular processes including cell growth and differentiation. By inhibiting JAK2 activity, LY2784544 helps scientists to understand the signaling mechanisms and functional consequences of this pathway in cellular models. The compound is also valuable in the investigation of signal transducer and activator of transcription (STAT) signaling cascades, as the JAK-STAT pathway is critical for transmitting information from extracellular chemical signals to the cell nucleus, resulting in DNA transcription. Additionally, LY2784544 enables the exploration of kinase enzyme regulation and the potential for modulation of these pathways, which are of interest in the study of cellular responses to environmental stimuli.
LY2784544 (CAS 1229236-86-5) References
- New generation small-molecule inhibitors in myeloproliferative neoplasms. | Passamonti, F., et al. 2012. Curr Opin Hematol. 19: 117-23. PMID: 22227528
- JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms. | Treliński, J. and Robak, T. 2013. Curr Med Chem. 20: 1147-61. PMID: 23317159
- Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. | Ma, L., et al. 2013. Blood Cancer J. 3: e109. PMID: 23584399
- Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. | Furqan, M., et al. 2013. Biomark Res. 1: 5. PMID: 24252238
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. | Rosenthal, A. and Mesa, RA. 2014. Expert Opin Pharmacother. 15: 1265-76. PMID: 24766055
- Photoredox catalysis in a complex pharmaceutical setting: toward the preparation of JAK2 inhibitor LY2784544. | Douglas, JJ., et al. 2014. J Org Chem. 79: 11631-43. PMID: 25356724
- Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells. | Telford, BJ., et al. 2015. Mol Cancer Ther. 14: 1213-23. PMID: 25777964
- Glycogen Synthase Kinase 3β Promotes the Endocytosis of Transferrin in the African Trypanosome. | Guyett, PJ., et al. 2016. ACS Infect Dis. 2: 518-28. PMID: 27626104
- Discovery and Characterization of Novel GPR39 Agonists Allosterically Modulated by Zinc. | Sato, S., et al. 2016. Mol Pharmacol. 90: 726-737. PMID: 27754899
- G Protein-Coupled Receptor 39 Agonist Improves Concanavalin A-Induced Hepatitis in Mice. | Muneoka, S., et al. 2019. Biol Pharm Bull. 42: 1415-1418. PMID: 31167986
- JAK2 inhibition in JAK2V617F-bearing leukemia cells enriches CD34+ leukemic stem cells that are abolished by the telomerase inhibitor GRN163L. | Dahlström, J., et al. 2020. Biochem Biophys Res Commun. 527: 425-431. PMID: 32334833
- Dnmt3a is downregulated by Stat5a and mediates G0/G1 arrest by suppressing the miR-17-5p/Cdkn1a axis in Jak2V617F cells. | Zhou, J., et al. 2021. BMC Cancer. 21: 1213. PMID: 34773997
- Artificial intelligence-driven consensus gene signatures for improving bladder cancer clinical outcomes identified by multi-center integration analysis. | Xu, H., et al. 2022. Mol Oncol. 16: 4023-4042. PMID: 36083778
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LY2784544, 5 mg | sc-364734 | 5 mg | $235.00 | |||
LY2784544, 25 mg | sc-364734A | 25 mg | $863.00 |